Rituximab has emerged as an alternative to cyclophosphamide for remission induction in anti-neutrophil cytoplasmic antibody-associated vasculitides, with recommendations now developed to direct its use in these diseases. However, data from extended clinical trials are required to determine whether rituximab is safer or more efficacious than cyclophosphamide in the long term.
- Julia U. Holle
- Wolfgang L. Gross
